Capital Fund Management (CFM)’s iShares Biotechnology ETF IBB Stock Holding History

Capital Fund Management (CFM)’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.32M	Sell	31,500 -71,200	-69%	-$12.2M	0.02%	866
2025 Q4	$17.3M	Sell	102,700 -8,600	-8%	-$1.4M	0.05%	556
2025 Q3	$16.1M	Buy	111,300 +22,300	+25%	+$3.04M	0.04%	614
2025 Q2	$11.3M	Buy	89,000 +46,100	+107%	+$5.66M	0.03%	691
2025 Q1	$5.49M	Sell	42,900 -16,100	-27%	-$2.18M	0.02%	968
2024 Q4	$7.8M	Buy	59,000 +11,700	+25%	+$1.64M	0.02%	869
2024 Q3	$6.89M	Sell	47,300 -71,800	-60%	-$10.4M	0.02%	874
2024 Q2	$16.3M	Buy	119,100 +29,000	+32%	+$3.87M	0.05%	484
2024 Q1	$12.4M	Sell	90,100 -38,300	-30%	-$5.23M	0.04%	639
2023 Q4	$17.4M	Buy	+128,400	New	+$15.7M	0.05%	520
2023 Q2	–	Sell	-95,200	Closed	-$12.3M	–	1771
2023 Q1	$12.3M	Buy	+95,200	New	+$12.5M	0.06%	430
2022 Q4	–	Sell	-10,900	Closed	-$1.27M	–	1484
2022 Q3	$1.27M	Sell	10,900 -2,800	-20%	-$348K	0.01%	1011
2022 Q2	$1.61M	Sell	13,700 -3,900	-22%	-$463K	0.01%	909
2022 Q1	$2.29M	Buy	17,600 +5,400	+44%	+$703K	0.02%	898
2021 Q4	$1.86M	Sell	12,200 -200	-2%	-$31K	0.01%	1059
2021 Q3	$2M	Buy	12,400 +2,000	+19%	+$337K	0.01%	941
2021 Q2	$1.7M	Sell	10,400 -5,500	-35%	-$847K	0.01%	1001
2021 Q1	$2.39M	Sell	15,900 -7,400	-32%	-$1.18M	0.03%	682
2020 Q4	$3.53M	Sell	23,300 -70,000	-75%	-$10M	0.03%	590
2020 Q3	$12.6M	Buy	93,300 +56,800	+156%	+$7.71M	0.16%	164
2020 Q2	$4.99M	Buy	36,500 +21,800	+148%	+$2.78M	0.08%	302
2020 Q1	$1.58M	Buy	14,700 +12,800	+674%	+$1.47M	0.02%	599
2019 Q4	$229K	Buy	+1,900	New	+$212K	﹤0.01%	1711
2019 Q3	–	Sell	-2,000	Closed	-$218K	–	1766
2019 Q2	$218K	Sell	2,000 -6,900	-78%	-$734K	﹤0.01%	1496
2019 Q1	$995K	Buy	8,900 +600	+7%	+$65.8K	0.01%	1038
2018 Q4	$800K	Sell	8,300 -6,200	-43%	-$658K	0.01%	1180
2018 Q3	$1.77M	Buy	14,500 +9,300	+179%	+$1.1M	0.01%	1167
2018 Q2	$571K	Buy	+5,200	New	+$556K	﹤0.01%	1546
2018 Q1	–	Sell	-99,400	Closed	-$10.6M	–	1986
2017 Q4	$10.6M	Buy	99,400 +41,200	+71%	+$4.4M	0.06%	385
2017 Q3	$6.47M	Buy	+58,200	New	+$6.22M	0.05%	464
2017 Q1	–	Sell	-56,100	Closed	-$4.96M	–	1626
2016 Q4	$4.96M	Sell	56,100 -62,400	-53%	-$5.68M	0.04%	499
2016 Q3	$11.4M	Sell	118,500 -327,000	-73%	-$31.1M	0.11%	239
2016 Q2	$38.2M	Buy	445,500 +18,900	+4%	+$1.7M	0.36%	65
2016 Q1	$37.1M	Buy	426,600 +298,200	+232%	+$26.7M	0.36%	68
2015 Q4	$14.5M	Sell	128,400 -53,700	-29%	-$5.83M	0.15%	184
2015 Q3	$18.4M	Sell	182,100 -26,400	-13%	-$3.17M	0.21%	127
2015 Q2	$25.6M	Buy	208,500 +128,100	+159%	+$15.3M	0.33%	74
2015 Q1	$9.2M	Sell	80,400 -6,000	-7%	-$662K	0.13%	208
2014 Q4	$8.74M	Sell	86,400 -59,400	-41%	-$5.77M	0.1%	265
2014 Q3	$13.3M	Buy	+145,800	New	+$12.8M	0.15%	163

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Fund Management (CFM)'s IBB Position: Q1 2026 in Review

Capital Fund Management (CFM) reduced its iShares Biotechnology ETF (IBB) stake by 39% in Q1 2026, selling an estimated $9M and leaving 81,298 shares worth $13.7M. The position accounts for 0.06% of the portfolio, ranked #431.

Capital Fund Management (CFM) first reported a position in IBB in Q3 2014 and has held it in 23 quarters since. The position peaked at $22.6M in Q4 2025. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Capital Fund Management (CFM) held 81,298 shares of iShares Biotechnology ETF worth $13.7M as of Q1 2026.
Capital Fund Management (CFM) sold 52,603 iShares Biotechnology ETF shares in Q1 2026, an estimated $9M.
iShares Biotechnology ETF made up 0.06% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #431 holding.
Capital Fund Management (CFM) first reported a position in iShares Biotechnology ETF in Q3 2014 and has held it in 23 quarters since.
Capital Fund Management (CFM)'s iShares Biotechnology ETF position peaked at $22.6M in Q4 2025.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.